Concord Healthcare Group (2453) H2 2025 earnings summary

Executive summary

• FY2025 revenue rose 18.4% YoY to RMB459.9m; gross profit turned positive at RMB32.0m from a RMB67.2m gross loss, and net loss narrowed 36.9% to RMB305.8m.

• Proton therapy growth at Guangzhou drove hospital performance, while medical equipment, software and related services revenue declined amid delayed market demand.

Financial highlights

• Revenue was RMB459.9m vs RMB388.3m in 2024; cost of revenue fell 6.1% to RMB428.0m.

• Gross profit was RMB32.0m vs a gross loss of RMB67.2m; net loss was RMB305.8m vs RMB484.8m.

• Administrative expenses fell 36.4% to RMB133.8m and R&D expenses fell 9.7% to RMB28.2m; finance costs rose 13.1% to RMB123.5m.

• Basic and diluted loss per share improved to RMB0.34 from RMB0.62.

Outlook and guidance

• Priorities include scaling proton therapy, integrating AI with clinical services and CSS, expanding overseas referral channels, and advancing Indonesia cooperation and asset-light growth.

• Plans include further AI product iteration, grassroots hospital empowerment, talent and research investment, international cooperation, and participation in industry standards.

• The proton center was expected to reach full-scale operations and provide recurring revenue; cash-flow forecasts through Dec. 31, 2026 underpin the going-concern assessment.